Effect of 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HCl (MKC-242), a novel 5-HT(1A)-receptor agonist, on aggressive behavior and marble burying behavior in mice

Japanese Journal of Pharmacology

Volumn 76, Issue 3, 1998, Pages 297-304

  Abe, Michikazu ^a   Nakai, Hiroshi ^a   Tabata, Reiko ^a   Saito, Ken Ichi ^a   Egawa, Mitsuo ^a  

^a MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

5 HT(1A) receptor; Aggressive behavior; Anxiolytic; Marble burying behavior; MKC 242

Indexed keywords

BUSPIRONE; CHLORPROMAZINE; DIAZEPAM; FLUOXETINE; OSEMOZOTAN; SEROTONIN 1A AGONIST; TANDOSPIRONE;

AGGRESSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONFLICT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG POTENCY; FIGHTING; MALE; MOTOR ACTIVITY; MOTOR COORDINATION; MOUSE; NONHUMAN; OBSESSION; ORAL DRUG ADMINISTRATION; RAT; SHOCK; TRANQUILIZING ACTIVITY;

EID: 0031945996     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.76.297     Document Type: Article

References (31)

1. Hoyer D and Martin G: 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36, 419-428 (1997)
2. Robinson DS: Buspirone in the treatment of anxiety. In Buspirone: Mechanisms and Clinical Aspects, Edited by Tunnicliff G, Eison AS and Taylor DP, pp 3-17, Academic Press Inc, San Diego (1991)
3. Murasaki M, Mori A, Endo S, Takemasa K, Hasegawa K, Kamijima K, Yagi G, Kudo Y, Nakajima T, Saito M, Nishimura T and Kawakita Y: Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis. Clin Eval 20, 295-329 (1992) (Abstr in English)
4. Insel TR, Zohar J, Benkelfat C and Murphy DL: Serotonin in obsessions, compulsions, and the control of aggressive impulses. In The Neuropharmacology of Serotonin, Edited by Whitaker-Azmitia PM and Peroutka SJ, pp 574-586, New York Academy of Sciences, New York (1990)
5. 1A) receptor responsivity in anxiety disorders and depression. In New Concepts in Anxiety, Edited by Briley M and File SE, pp 130-144, Macmillan Press, London (1991)
6. Jenike MA and Baer L: An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 145, 1285-1286 (1988)
7. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S and Murphy DL: Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 148, 127-129 (1991)
8. Garattini S: Neurochemical profile of buspirone. In Buspirone: Mechanisms and Clinical Aspects, Edited by Tunnicliff G, Eison AS and Taylor DP, pp 151-162, Academic Press Inc, San Diego (1991)
9. Barrett JE, Witkin JM, Mansbach RS, Skolnick P and Weissman BA: Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. J Pharmacol Exp Ther 238, 1009-1013 (1986)
10. Przegaliński E, Tatarczyńska E and Chojnacka-Wójcik E: Anti-conflict effect of ipsapirone, buspirone and gepirone is not mediated by their common metabolite 1-(2-pyrimidinyl)piperazine. Journal of Psychopharmacology 3, 180-185 (1989)
11. 2-Adrenoceptor antagonist activity may account for the effects of buspirone in an anti-conflict test in the rat. Eur J Pharmacol 155, 129-137 (1988)
12. Pellow S, Chopin P, File SE and Briley M: Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14, 149-167 (1985)
13. Caccia S, Conti I, Vigano G and Garattini S: 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology 33, 46-51 (1986)
14. Abe M, Tabata R, Saito K-I, Matsuda T, Baba A and Egawa M: Novel benzodioxan derivative, 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. J Pharmacol Exp Ther 278, 898-905 (1996)
15. 1A receptors. Jpn J Pharmacol 69, 357-366 (1995)
16. 1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68, 65-70 (1995)
17. Tedeschi RE, Tedeschi DH, Mucha A, Cook L, Mattis PA and Fellows EJ: Effects of various centrally acting drugs on fighting behavior of mice. J Pharmacol Exp Ther 125, 28-34 (1958)
18. Yen CY, Stanger RL and Millman N: Atractic supplession of isolation-induced aggressive behavior. Arch Int Pharmacodyn Ther 123, 179-185 (1959)
19. Vogel JR, Beer B and Clody DE: A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia (Berl) 21, 1-7 (1971)
20. Treit D: Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9, 203-222 (1985)
21. Riblet LA, Eison AS, Eison MS, Newton RE, Taylor DP and Temple DL Jr: Buspirone: an anxioselective alternative for the treatment of anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry 7, 663-668 (1983)
22. White SM, Kucharik RF and Moyer JA: Effects of serotonergic agents on isolation-induced aggression. Pharmacol Biochem Behav 39, 729-736 (1991)
23. 1A agonists buspirone and gepirone. Pharmacol Biochem Behav 31, 269-278 (1988)
24. McMillen BA, Scott SM, Williams HL and Sanghera MK: Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 335, 454-464 (1987)
25. Shimizu H, Tatsuno T, Tanaka H, Hirose A, Araki Y and Nakamura M: Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 59, 105-112 (1992)
26. 1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur J Pharmacol 249, 341-351 (1993)
27. Njung'e K and Handley SL: Evaluation of marble burying as a model of anxiety. Pharmacol Biochem Behav 38, 63-67 (1991)
28. Broekkamp CL, Rijk HW, Joly-Gelouin D and Lloyd KL: Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126, 223-229 (1986)
29. Njung'e K and Handley SL: Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104, 105-112 (1991)
30. Insel TR, Mueller EA, Alterman I Linnoila M and Murphy DL: Obsessive-compulsive disorder and serotonin: Is there a connection? Biol Psychiatry 20, 1174-1189 (1985)
31. Thorén P, Åsberg M and Bertilsson L: Clomipramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 37, 1289-1294 (1980)